China Pharma Holdings (CPHI) Notes Payables (2010 - 2026)

China Pharma Holdings has reported Notes Payables for 13 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 27.12% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 27.12% YoY), and the FY2025 full-year result was $1.4 million, up 25.34% from the prior year.
• Notes Payables for Q1 2026 stood at $1.5 million, up from $1.4 million in the prior quarter.
• The five-year high for Notes Payables was $4.6 million in Q3 2022, with the low at $315428.0 in Q3 2024.
• Historically, Notes Payables has averaged $1.7 million across 5 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2024 — Notes Payables plunged 84.44% — and 2025, when it surged 348.07%.
• China Pharma Holdings' Notes Payables stood at $3.8 million in 2022, then tumbled by 70.16% to $1.1 million in 2023, then grew by 0.99% to $1.1 million in 2024, then increased by 25.34% to $1.4 million in 2025, then rose by 2.16% to $1.5 million in 2026.
• The last three Notes Payables figures came in at $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.